|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 350.60 USD | +3.81% |
|
+1.43% | +7.09% |
| 11:03pm | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 07:01pm | Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial | RE |
| Market Cap | 182B 158B 146B 137B 255B 17,453B 261B 1,739B 673B 8,413B 684B 670B 29,252B | P/E Ratio 2026 * |
22x | P/E Ratio 2027 * | 20x |
|---|---|---|---|---|---|
| Enterprise Value | 224B 194B 179B 168B 313B 21,401B 320B 2,133B 826B 10,316B 839B 821B 35,869B | EV / Sales 2026 * |
5.91x | EV / Sales 2027 * | 5.61x |
| Free-Float |
99.78% | Yield 2026 * |
2.99% | Yield 2027 * | 3.16% |
Last Transcript: Amgen Inc.
| 1 day | +3.80% | ||
| 1 week | +1.43% | ||
| Current month | +4.08% | ||
| 1 month | +6.35% | ||
| 3 months | -7.18% | ||
| 6 months | +10.44% | ||
| Current year | +7.09% |
| 1 week | 337.49 |  | 356.5 |
| 1 month | 320.96 | | 356.5 |
| Current year | 318.21 | | 391.29 |
| 1 year | 267.83 | | 391.29 |
| 3 years | 215.32 | | 391.29 |
| 5 years | 198.64 | | 391.29 |
| 10 years | 133.64 | | 391.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 01/05/2012 |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 01/01/2020 |
Esteban Santos
COO | Chief Operating Officer | 59 | 25/07/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 01/01/2013 |
Tyler Jacks
BRD | Director/Board Member | 65 | 01/01/2012 |
Robert Eckert
BRD | Director/Board Member | 71 | 01/01/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-19 | Free | Director | 665 | 0.0001% | ||
| 05-19 | Free | Director | 665 | 0.0001% | ||
| 05-19 | Free | Director | 665 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.81% | +1.43% | +20.12% | +61.27% | 182B | |
| +1.62% | +2.64% | +42.84% | +159.37% | 1,013B | |
| +0.48% | +5.08% | +54.43% | +49.95% | 574B | |
| +0.26% | +0.24% | +17.75% | +63.72% | 397B | |
| -0.37% | +4.97% | +21.24% | +15.95% | 324B | |
| +0.85% | +0.18% | +24.50% | +14.78% | 280B | |
| +2.10% | +4.92% | +25.30% | +33.80% | 273B | |
| -0.19% | -0.46% | -45.32% | -48.35% | 194B | |
| +3.28% | -2.80% | +14.88% | +61.26% | 151B | |
| +2.17% | +1.75% | +6.78% | -34.49% | 146B | |
| Average | +1.38% | +2.48% | +18.25% | +37.73% | 353.45B | |
| Weighted average by Cap. | +1.16% | +3.87% | +28.42% | +67.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.79B 32.8B 30.23B 28.33B 52.93B 3,619B 54.03B 361B 140B 1,744B 142B 139B 6,065B | 38.75B 33.63B 31B 29.05B 54.27B 3,711B 55.4B 370B 143B 1,789B 145B 142B 6,219B |
| Net income | 8.26B 7.17B 6.61B 6.19B 11.57B 791B 11.82B 78.86B 30.53B 381B 31.03B 30.36B 1,326B | 9.04B 7.85B 7.23B 6.78B 12.66B 866B 12.92B 86.27B 33.4B 417B 33.94B 33.21B 1,451B |
| Net Debt | 41.23B 35.78B 32.98B 30.9B 57.74B 3,948B 58.94B 393B 152B 1,903B 155B 151B 6,617B | 35.08B 30.44B 28.06B 26.3B 49.13B 3,359B 50.15B 335B 130B 1,619B 132B 129B 5,630B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/26 | 350.56 $ | +3.80% | 2,166,063 |
| 10/06/26 | 337.73 $ | -1.98% | 3,000,395 |
| 09/06/26 | 344.56 $ | -0.34% | 3,388,246 |
| 08/06/26 | 345.73 $ | -1.10% | 2,488,219 |
| 05/06/26 | 349.58 $ | +1.15% | 3,451,237 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition